Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
9.81
-0.27 (-2.68%)
Apr 28, 2026, 4:00 PM EDT - Market closed
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
36
Market Cap
173.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 881.71K | -3.06M | -77.61% |
| Dec 31, 2020 | 3.94M | -32.21M | -89.11% |
| Dec 31, 2019 | 36.14M | 31.32M | 649.51% |
| Dec 31, 2018 | 4.82M | 2.38M | 97.62% |
| Dec 31, 2017 | 2.44M | 528.78K | 27.66% |
| Dec 31, 2016 | 1.91M | 1.26M | 194.80% |
| Dec 31, 2015 | 648.38K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Protalix BioTherapeutics | 52.74M |
| Precision BioSciences | 34.26M |
| Tonix Pharmaceuticals Holding | 13.11M |
| Korro Bio | 6.39M |
| Cartesian Therapeutics | 2.80M |
| Humacyte | 2.04M |
CRBP News
- 21 days ago - Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Benzinga
- 7 weeks ago - Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals Holdings Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference - Transcripts
- 4 months ago - Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals Holdings Transcript: Study Update - Transcripts
- 4 months ago - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewsWire